Kinarus develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.
Kinarus has raised €73M across 2 funding rounds from 2 investors, most recently a Debt round in Aug 2022. Based in Basel, Switzerland; active in Healthtech. Acquired by Curatis in 2024. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-22 | Debt | €21M | YA II PN | View deal → |
| 2021-09-16 | Other | €52M |
| View deal → |
